OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
The SMILE trial will seek to identify individuals at high risk for developing lupus and treat them before they ever transition into the disease.
OMRF’s Christopher Hoover became just the second Oklahoman in 30 years to earn a prestigious Kirschstein service award.
New findings could help scientists develop treatments for the condition known as ITP.
This collaboration is part of GSK’s “Discovery Partnerships with Academia” (DPAc) efforts.
Lupu’s findings were published in the Proceedings of the National Academy of Sciences.